1	
2	
3	Molnupiravir or nirmatrelvir-ritonavir versus usual
4	care in patients admitted to hospital with COVID-19
5	(RECOVERY): a randomised, controlled, open-label,
6	platform trial
7	
8	Running title: Molnupiravir or nirmatrelvir-ritonavir for COVID-19
9	RECOVERY Collaborative Group*
10	
11	
12	*The writing committee and trial steering committee are listed at the end of this
13	manuscript and a complete list of collaborators in the Randomised Evaluation of
14	COVID-19 Therapy (RECOVERY) trial is provided in the Supplementary Appendix.
15	
16	Correspondence to: Prof Peter W Horby and Prof Martin J Landray, RECOVERY Central
17	Coordinating Office, Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford OX3
18	7LF, United Kingdom.
19	Email: recoverytrial@ndph.ox.ac.uk

21 SUMMARY

Background: Molnupiravir and nirmatrelvir-ritonavir (Paxlovid) are oral antivirals that
 have been proposed as treatments for patients admitted to hospital with COVID-19.

24 Methods: In this randomised, controlled, open-label, adaptive platform trial, several 25 potential treatments for patients hospitalised with COVID-19 pneumonia were evaluated. 26 Molnupiravir and nirmatrelvir-ritonavir were assessed in separate comparisons in 27 RECOVERY, both of which are reported here. Eligible and consenting adults could join 28 the molnupiravir comparison, the nirmatrelvir-ritonavir comparison, or both. For each 29 comparison, participants were randomly allocated in a 1:1 ratio to the relevant antiviral 30 (five days of molnupiravir 800mg twice daily or nirmatrelvir-ritonavir 300mg/100mg twice 31 daily) or to usual care without the relevant antiviral drug, using web-based unstratified 32 randomisation with allocation concealment. The primary outcome was 28-day mortality, 33 and secondary outcomes were time to discharge alive from hospital, and among those 34 not on invasive ventilation at baseline, progression to invasive ventilation or death. Analysis was by intention-to-treat. Both comparisons were stopped by the investigators 35 because of low recruitment. ISRCTN (50189673) and clinicaltrials.gov (NCT04381936). 36

Findings: From 24 January 2022 to 24 May 2023, 923 patients were recruited to the molnupiravir comparison (445 allocated molnupiravir and 478 allocated usual care), and from 31 March 2022 to 24 May 2023, 137 patients were recruited to the nirmatrelvirritonavir comparison (68 allocated nirmatrelvir-ritonavir and 69 allocated usual care). More than three-quarters of the patients in both comparisons were vaccinated and had anti-spike antibodies at randomisation, and more than two-thirds were receiving other

43 SARS-CoV-2 antivirals (including remdesivir or sotrovimab). In the molnupiravir 44 comparison, 74 (17%) patients allocated to molnupiravir and 79 (17%) patients allocated usual care died within 28 days (hazard ratio [HR] 0.93; 95% confidence interval [CI] 0.68-45 46 1.28; p=0.66). In the nirmatrelvir-ritonavir comparison, 13 (19%) patients allocated 47 nirmatrelvir-ritonavir and 13 (19%) patients allocated usual care died within 28 days (HR 1.02; 95% CI 0.47-2.23; p=0.96). In neither comparison was there evidence of a 48 49 significant difference in the duration of hospitalisation or the proportion of patients progressing to invasive ventilation or death. 50

51 **Interpretation:** In adults hospitalised with COVID-19, neither molnupiravir nor 52 nirmatrelvir-ritonavir were associated with reductions in 28-day mortality, duration of 53 hospital stay, or risk of progressing to invasive mechanical ventilation or death although 54 these comparisons had limited statistical power due to low recruitment.

Funding: UK Research and Innovation (Medical Research Council) and National Institute
of Health and Care Research (Grant ref: MC_PC_19056), and Wellcome Trust (Grant
Ref: 222406/Z/20/Z).

- 58 **Trial registration:** ClinicalTrials.gov NCT04381936
- 59 https://clinicaltrials.gov/ct2/show/NCT04381936
- 60 ISRCTN50189673 http://www.isrctn.com/ISRCTN50189673
- 61 **Keywords:** COVID-19, molnupiravir, nirmatrelvir, clinical trial.

63 **INTRODUCTION**

64 Early antiviral treatment of unvaccinated patients at high risk of severe COVID-19 can substantially reduce the risk of subsequent hospitalisation or death.^{1–3} There is less 65 evidence supporting antiviral treatment in people admitted to hospital, and in these 66 patients it may be that immune-mediated lung damage, rather than ongoing viral 67 replication, is primarily responsible for disease progression. Antiviral treatment with 68 neutralising monoclonal antibodies (nMAb) has been shown to substantially reduce 69 mortality in hospitalised patients, but only in those not yet producing their own anti-SARS-70 71 CoV-2 antibodies.⁴ However, most immunocompetent adults now have some SARS-72 COV-2 immunity following vaccination or previous infection, and the available nMAbs are now largely ineffective because of spike gene mutations in globally prevalent SARS-COV-73 2 variants.^{5,6} Remdesivir, a nucleoside analogue inhibitor of the viral RNA-dependent 74 75 RNA polymerase, reduces time-to-discharge by around one day in hospitalised patients and is associated with a moderate reduction in mortality, at least in non-ventilated 76 patients.^{7,8} Other potent SARS-CoV-2 antivirals, including molnupiravir and nirmatrelvir-77 ritonavir (Paxlovid), have not been adequately tested in randomised trials in hospitalised 78 79 patients, and it could be that these drugs, given alone or in combination with other 80 antivirals, would improve clinical outcomes.

Molnupiravir is an orally absorbed prodrug of N(4)-Hydroxycytidine, a nucleosideanalogue substrate of the viral RNA-dependent RNA polymerase. It has a broad spectrum of activity against RNA viruses, including coronaviruses, and a high barrier to the development of viral resistance.^{9–11} Its mechanism of action is distinct to remdesivir,

85 impairing viral RNA replication by facilitating ambiguous base pairing, leading to an 86 accumulation of transversion mutations. In the MOVe-OUT trial, early treatment of highrisk unvaccinated patients with COVID-19 reduced the risk of hospitalisation or death by 87 88 30% (risk ratio[RR] 0.70; 95% CI 0.49-0.99; p=0.045), but no significant benefit was shown in the subsequent PANORAMIC trial among lower-risk, vaccinated patients 89 infected with Omicron variants (RR 1.07; 95% CI 0.81-1.41; p=0.5).^{12,13} MOVe-IN is the 90 91 only reported trial of molnupiravir in hospitalised patients, which included 304 92 unvaccinated individuals.¹⁴ This found no significant difference in the primary outcome of recovery by day 29 (84% molnupiravir group vs. 85% placebo group), or mortality (6% 93 94 molnupiravir group vs. 3% placebo group), but was underpowered to rule out worthwhile improvements in either outcome. 95

96 Nirmatrelvir is an orally administered small-molecule inhibitor of the viral 3-chymotrypsin-97 like (3CL) protease, which is co-administered with ritonavir to enhance its pharmacokinetics.¹⁵ In the EPIC-HR trial of high-risk unvaccinated patients with early 98 COVID-19 it reduced the risk of hospitalisation or death by 88% (RR 0.12; 95% CI 0.06-99 100 0.25; p<0.0001) although no significant benefit was present in the subsequent EPIC-SR 101 trial of vaccinated and lower risk patients (RR 0.48; 95% CI 0.17-1.41; p=0.18).^{3,16} Only 102 one trial has reported nirmatrely rritonavir use in hospitalised patients, which included 103 264 patients.¹⁷ In this trial there was no significant difference in the primary outcome of 104 28-day mortality (4% nirmatrelvir-ritonavir group vs. 6% standard treatment group), but it 105 was underpowered to rule out a worthwhile benefit of treatment.

106

107 Here we report the results of independent evaluations of molnupiravir and nirmatrelvir-

108 ritonavir versus usual care in the RECOVERY trial, a randomised, open-label platform

trial evaluating treatments for patients hospitalised with COVID-19 pneumonia.

110

111 METHODS

112 Study design and participants

113 The Randomised Evaluation of COVID-19 therapy (RECOVERY) trial is an investigatorinitiated, individually randomised, controlled, open-label, adaptive platform trial to 114 115 evaluate the effects of potential treatments in patients hospitalised with COVID-19. 116 Details of the trial design and results for other treatments have been published previously 117 (dexamethasone, hydroxychloroquine, lopinavir-ritonavir, azithromycin, tocilizumab, 118 convalescent plasma, colchicine, aspirin, casirivimab plus imdevimab, baricitinib, 119 empagliflozin, dimethyl fumarate, and high-dose corticosteroids in hypoxic patients not requiring ventilatory support).^{4,18–29} The trial was conducted at hospital organisations in 120 121 the United Kingdom supported by the National Institute for Health and Care Research 122 Clinical Research Network, as well as in South and Southeast Asia and Africa. Of these, 123 75 hospitals in the UK, 2 in Nepal, and 2 in Indonesia enrolled participants in the molnupiravir comparison, and 32 UK hospitals enrolled participants in the nirmatrelvir-124 125 ritonavir comparison (appendix pp 2-31). The trial is coordinated by the Nuffield Department of Population Health at University of Oxford (Oxford, UK), the trial sponsor. 126 The trial is conducted in accordance with the principles of the International Conference 127 128 on Harmonisation–Good Clinical Practice guidelines and approved by the UK Medicines

and Healthcare products Regulatory Agency (MHRA) and the Cambridge East Research
Ethics Committee (ref: 20/EE/0101). The protocol, statistical analysis plan, and additional
information are available on the study website www.recoverytrial.net.

132 Patients admitted to hospital were eligible for the study if they had confirmed SARS-CoV-133 2 infection with a pneumonia syndrome thought to be related to COVID-19, and no 134 medical history that might, in the opinion of the managing physician, put the patient at significant risk if they were to participate in the trial. Patients were excluded from the 135 136 molnupiravir comparison if (i) they were pregnant or breastfeeding, or (ii) they had received molnupiravir during their current illness. Patients were excluded from the 137 138 nirmatrelvir-ritonavir comparison if (i) they were in the first trimester of pregnancy, (ii) had severe liver impairment (Child-Pugh class C), (iii) had severe renal impairment (eGFR 139 140 <30ml/min/1.73m²), (iv) had received nirmatrelvir-ritonavir during their current illness, or (v) were receiving a concomitant medication with CYP3A4 dependent metabolism that 141 142 risked a severe drug-drug interaction with nirmatrelvir-ritonavir. Children (age <18 years) 143 and those unable to take medication orally were excluded from both comparisons. If a 144 study treatment was unavailable, or if the managing physician considered a study 145 treatment to be either definitely indicated or definitely contraindicated, then patients were 146 excluded from the relevant comparison. Written informed consent was obtained from all patients, or a legal representative if patients were too unwell or otherwise unable to 147 148 provide informed consent.

149 Randomisation and masking

150 Baseline data were collected using a web-based case report form that included 151 demographics, level of respiratory support, major comorbidities, suitability of the study treatment for a particular patient, SARS-CoV-2 vaccination status, and study treatment 152 153 availability at the study site (appendix pp 43-46). A serum sample and nose swab were 154 collected at randomisation from UK patients and sent to central laboratories for testing. Serum was tested for anti-SARS-CoV-2 spike antibodies, anti-SARS-CoV-2 nucleocapsid 155 156 antibodies, and SARS-CoV-2 nucleocapsid antigen using Roche Elecsys assays (Roche 157 Diagnostics, Basel, Switzerland). Patients were classified as positive or negative for anti-158 spike and anti-nucleocapsid antibodies using manufacturer defined thresholds, and as 159 positive or negative for serum nucleocapsid antigen using the study population median value (as this assay had not previously been validated on serum samples). Nose swabs 160 161 were tested for SARS-CoV-2 RNA using TagPath COVID-19 RT-PCR (Thermo Fisher Scientific, Massachusetts, US). Samples with sufficient concentration of viral RNA were 162 163 sequenced using the ONT Midnight protocol (Oxford Nanopore Technologies, Oxford, 164 UK).³⁰ Sequence data were used to detect mutations associated with resistance to 165 molnupiravir or nirmatrelvir-ritonavir identified from literature searches. Further details of 166 laboratory analyses are in the appendix (pp 32-33).

Patients could enter either one or both of the comparisons provided they were eligible. For each comparison they entered, patients were randomly assigned in a 1:1 ratio to either usual standard of care plus the relevant treatment or usual standard of care without the relevant treatment, using web-based simple (unstratified) randomisation with allocation concealed until after randomisation (appendix pp 41-43). Patients allocated to molnupiravir were to receive 800mg orally twice daily for 5 days. Patients allocated to

nirmatrelvir-ritonavir were to receive 300mg/100mg orally twice daily for 5 days, reduced
to 150mg/100mg twice daily if they had moderate renal impairment (eGFR 3059ml/min/1.73m²). In both comparisons the course was to be continued after discharge if
required.

As a platform trial, and in a factorial design, patients could be simultaneously randomised to other concurrently evaluated treatment groups: (i) empagliflozin versus usual care, (ii) higher-dose corticosteroids versus usual care, (iii) sotrovimab versus usual care (appendix pp 41-42). Participants and local study staff were not masked to allocated treatment. Other than members of the Data Monitoring Committee, all individuals involved in the trial were masked to aggregated outcome data while recruitment and 28-day followup were ongoing.

184

185 **Procedures**

Follow-up nose swabs were collected from UK patients on day 3 and day 5 (counting the day of randomisation as day 1). These were analysed in the same manner as the baseline swab described above.

A single online follow-up form was completed when participants were discharged, had died or at 28 days after randomisation, whichever occurred earliest (appendix pp 47-55). Information was recorded on adherence to allocated study treatment, receipt of other COVID-19 treatments, duration of admission, receipt of respiratory or renal support, and vital status (including cause of death). In addition, in the UK, routine healthcare and

registry data were obtained, including information on vital status (with date and cause of death), discharge from hospital, receipt of respiratory support, or renal replacement therapy. For sites outside the UK a further case report form (appendix pp 56-57) collected vital status at day 28 (if not already reported on the initial follow-up form).

198 Outcomes

199 Outcomes were assessed at 28 days after randomisation, with further analyses specified 200 at 6 months. The primary outcome was all-cause mortality at 28 days. Secondary 201 outcomes were time to discharge from hospital, and, among patients not on invasive 202 mechanical ventilation at randomisation, invasive mechanical ventilation (including extracorporal membrane oxygenation) or death. Prespecified subsidiary clinical outcomes 203 204 were use of non-invasive respiratory support, time to successful cessation of invasive 205 mechanical ventilation (defined as cessation of invasive mechanical ventilation within, 206 and survival to, 28 days), use of renal dialysis or haemofiltration, cause-specific mortality, 207 bleeding events, thrombotic events, major cardiac arrhythmias, non-SARS-CoV-2 208 infections, and metabolic complications (including ketoacidosis). Virological outcomes 209 were viral RNA levels in nose swabs taken at day 3 and day 5, and the frequency of 210 detection of resistance markers. Information on suspected serious adverse reactions was 211 collected in an expedited fashion to comply with regulatory requirements.

212

213 Sample size

The intention for this comparison was to continue recruitment until sufficient primary outcomes had accrued to have 90% power to detect a proportional risk reduction of 20% at a two-sided significance level of 0.01.

Following the initial wave of Omicron infection in the UK in early 2022, the number of patients hospitalised with COVID-19 pneumonia reduced substantially in the UK, as did recruitment to both comparisons. Because of persistently low recruitment, the RECOVERY Trial Steering Committee decided to close both comparisons on 24th May 2023 whilst still blinded to the results.

222

223 Statistical Analysis

224 The primary analysis for all outcomes was by intention-to-treat, comparing patients 225 randomised to the study treatment with patients randomised to usual care but for whom 226 that study treatment was both available and suitable as a treatment. For the primary 227 outcome of 28-day mortality, the hazard ratio from an age- and respiratory status-adjusted Cox model was used to estimate the mortality rate ratio. We constructed Kaplan-Meier 228 survival curves to display cumulative mortality over the 28-day period. We used the same 229 230 Cox regression method to analyse time to hospital discharge and successful cessation of 231 invasive mechanical ventilation, with patients who died in hospital right-censored on day 232 29. Median time to discharge was derived from Kaplan-Meier estimates. For the pre-233 specified composite secondary outcome of progression to invasive mechanical ventilation or death within 28 days (among those not receiving invasive mechanical ventilation at 234 235 randomisation), and the subsidiary clinical outcomes of receipt of invasive or non-invasive

ventilation, or use of haemodialysis or haemofiltration, the precise dates were not available and so a log-binomial regression model was used to estimate the risk ratio adjusted for age and respiratory status. SARS-CoV-2 viral RNA levels in nose-swabs were estimated with analysis of covariance (ANCOVA) using the log transformed values after adjustment for each participant's baseline value, age and level of respiratory support at randomisation.

Prespecified subgroup analyses were performed for the primary outcome using the statistical test of interaction (test for heterogeneity or trend), in accordance with the prespecified analysis plan, defined by the following characteristics at randomisation: age, sex, ethnicity, level of respiratory support, days since symptom onset, and use of corticosteroids (appendix p 135). Exploratory sub-group analyses were also performed by SARS-COV-2 antibody status (anti-S and anti-N), serum nucleocapsid antigen status, and use of other antivirals.

Estimates of rate and risk ratios are shown with 95% confidence intervals. All p-values are 2-sided and are shown without adjustment for multiple testing. The full database is held by the study team, which collected the data from study sites and performed the analyses at the Nuffield Department of Population Health, University of Oxford (Oxford, UK).

Analyses were performed using SAS version 9.4 and R version 3.4. The trial is registered
with ISRCTN (50189673) and clinicaltrials.gov (NCT04381936).

256 Role of the funding source

Neither the study funders, nor the manufacturers of molnupiravir or nirmatrelvir-ritonavir, had any role in study design, data collection, data analysis, data interpretation, or writing of the report. Molnupiravir and nirmatrelvir-ritonavir were supplied by the UK government in the UK, and bought from commercial suppliers in Nepal and Indonesia. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.

263

264 **RESULTS**

265 Molnupiravir comparison

266 Between 24 January 2022 and 24 May 2023, 923/1242 (74%) patients enrolled in 267 RECOVERY at sites participating in the molnupiravir comparison were eligible to be 268 randomly allocated to molnupiravir, of whom 445 were allocated molnupiravir and 478 269 were allocated usual care without molnupiravir (figure 1A). The 319 RECOVERY patients 270 not included in the molnupiravir comparison had similar characteristics to those included 271 (webtable 1). The mean age of study participants in this comparison was 71.4 years (SD 272 14.1), 767 (83%) had received a COVID-19 vaccine, and the median time since symptom 273 onset was 5 days (IQR 3 to 9 days). 133/923 (14%) patients in the molnupiravir 274 comparison simultaneously participated in the nirmatrelvir-ritonavir comparison. At 275 randomisation, 809 (88%) patients were receiving corticosteroids, and 629 (68%) were 276 receiving, or allocated to receive, a SARS-CoV-2 antiviral other than molnupiravir 277 (including usual care remdesivir, and sotrovimab or nirmatrelvir-ritonavir allocated in

another RECOVERY comparison). 227 (25%) patients were anti-N seropositive and 705
(76%) were anti-S seropositive.

280 The follow-up form was completed for 915 (99%) patients, and among them, 413/443 281 (93%) in the molnupiravir group received at least one dose of molnupiravir, compared to 282 0/472 (0%) in the usual care group (webtable 3). Primary and secondary outcome data 283 are known for >99% of randomly assigned patients. There was no evidence of a 284 significant difference in the proportion of patients who met the primary outcome of 28-day 285 mortality between the two randomised groups (74 [17%] patients in the molnupiravir group vs. 79 [17%] patients in the usual care group; hazard ratio 0.93; 95% confidence interval 286 [CI], 0.68-1.28; p=0.66; table 2, figure 2A). We observed similar results in all pre-specified 287 288 sub-groups, and in exploratory subgroups defined by serum SARS-CoV-2 antigen or 289 antibody status, and use of other SARS-CoV-2 antiviral treatments (figure 3).

There was no evidence of a significant difference in the probability of being discharged alive within 28 days (72% vs. 74%, rate ratio 0.96, 95% CI 0.82 to 1.12, p=0.60) (table 2). Among those not on invasive mechanical ventilation at baseline, the number of patients progressing to the pre-specified composite secondary outcome of invasive mechanical ventilation or death was similar in both groups (17% vs. 17%, risk ratio 0.96, 95% CI 0.73 to 1.25, p=0.75). Similar results were seen in all pre-specified subgroups of patients (webfigures 1 and 2).

We found no evidence of significant differences in prespecified subsidiary clinical outcomes or cause-specific mortality between groups (table 2, webtable 4). There were more episodes of hyperglycaemia requiring insulin in patients allocated to molnupiravir

versus usual care (7.4% vs 3.1%, absolute difference 4.3%, [95% CI 1.4-7.2] p=0.0038)
 (webtable 5). The rates of other safety outcomes were similar between groups, including
 new cardiac arrhythmia, thrombotic events, clinically significant bleeds, non-coronavirus
 infections, seizures, acute liver injury, and acute kidney injury (webtable 5). There were
 no reported suspected serious adverse reactions in patients allocated molnupiravir.

305 872/893 (98%) of UK patients had at least one nose swab available for analysis. 306 Allocation to molnupiravir was associated with a lower baseline-adjusted viral load in nose 307 swabs taken on day 5 (-0.48 log₁₀ copies/ml; 95% CI -0.80 to -0.16; p=0.0037), but not 308 on day 3 (table 2). 622 (67%) patients had at least one successfully sequenced sample 309 with \geq 90% genome coverage, and of these 620 (>99%) were Omicron variants (primarily 310 BA.1, BA.2, BA.5, and XBB). No candidate molnupiravir resistance mutations were 311 identified from literature searches, so we were not able evaluate baseline or follow-up 312 nose swabs for mutations associated with resistance.

313

314 Nirmatrelvir-ritonavir comparison

Between 31 March 2022 and 24 May 2023, 137/494 (28%) of patients recruited at sites participating in the nirmatrelvir-ritonavir comparison were eligible to be randomly allocated to nirmatrelvir-ritonavir, of whom 68 were allocated nirmatrelvir-ritonavir and 69 allocated to usual care without nirmatrelvir-ritonavir (figure 1B). The 357 RECOVERY patients not included in the nirmatrelvir-ritonavir comparison had similar characteristics to those included (webtable 2). The mean age of study participants in this comparison was 72.5 years (SD 13.9), 116 (85%) had received a COVID-19 vaccine, and the median time

since symptom onset was 4 days (IQR 3 to 8 days). 133 (97%) patients participating in the nirmatrelvir-ritonavir comparison also participated in the molnupiravir comparison. At randomisation, 122 (89%) patients were receiving corticosteroids, and 111 (81%) were receiving, or allocated to receive, a SARS-CoV-2 antiviral other than nirmatrelvir-ritonavir (including usual care remdesivir, and sotrovimab or molnupiravir allocated in another RECOVERY comparison). 40 (29%) patients were anti-N seropositive and 112 (82%) were anti-S seropositive.

329 The follow-up form was completed for 135 (99%) patients, and among them, 60/67 (90%) 330 in the nirmatrelvir-ritonavir group received at least one dose of nirmatrelvir-ritonavir, compared to 0/68 (0%) in the usual care group (webtable 3). Primary and secondary 331 332 outcome data are known for >99% of randomly assigned patients. There was no evidence of a significant difference in the proportion of patients who met the primary outcome of 333 334 28-day mortality between the two randomised groups (13 [19%] patients in the 335 nirmatrelvir-ritonavir group vs. 13 [19%] patients in the usual care group; hazard ratio 1.02; 336 95% CI, 0.47-2.23; p=0.96; table 2, figure 2B). Because of low recruitment to this 337 comparison, no subgroup analyses were performed.

There was no evidence of a significant difference in the probability of being discharged alive within 28 days (71% vs. 78%, rate ratio 0.80, 95% CI 0.54 to 1.20, p=0.29) (table 2). Among those not on invasive mechanical ventilation at baseline, the number of patients progressing to the pre-specified composite secondary outcome of invasive mechanical ventilation or death was similar in both groups (21% vs. 19%, risk ratio 1.06, 95% CI 0.54 to 2.08, p=0.86).

We found no evidence of significant differences in prespecified subsidiary clinical outcomes or cause-specific mortality between groups (table 2, webtable 4). The rates of all safety outcomes were similar between groups (webtable 5). There were no reported suspected serious adverse reactions in patients allocated nirmatrelvir-ritonavir.

All patients had at least one nose swab available for analysis. Allocation to nirmatrelvirritonavir was associated with a significantly lower baseline-adjusted viral load in nose swabs taken on day 5 (-0.68 log₁₀ copies/ml; 95% CI -1.29 to -0.07; p=0.03), but not on day 3 (table 2). 97 (71%) patients had at least one sample successfully sequenced with \geq 90% genome coverage, and of these 96 (99%) were Omicron variants. No sequenced samples contained mutations at the 20 nucleotide positions in the 3CL protease that had previously been associated with >2.5 fold median reduction in inhibition by nirmatrelvir.

355

356 **DISCUSSION**

In these two reported evaluations from the RECOVERY trial, among patients admitted to hospital for severe COVID-19, neither molnupiravir nor nirmatrelvir-ritonavir was found to reduce mortality, duration of hospitalisation, or the risk of being ventilated or dying for those not on ventilation at baseline. However, both comparisons lacked statistical power to exclude modest differences in these outcomes.

362 Previous trials have indicated the potential benefit of antiviral treatment with nMAbs or 363 remdesivir in hospitalised patients, but randomised evidence has been inadequate for 364 molnupiravir and nirmatrelvir-ritonavir, two widely available antivirals with efficacy in early

infection. For each drug, only one other randomised trial in hospitalised COVID-19 patients has been reported to date, but neither were large enough to detect plausibly moderate benefits of treatment.^{14,17} The present RECOVERY comparisons were both stopped because of low recruitment before they had reached the planned sample size, with 923 patients recruited to the molnupiravir comparison and 137 recruited to the nirmatrelvir-ritonavir comparison. Our results do not suggest any benefit in adding these antivirals to routine care, but limited recruitment means we cannot exclude a benefit.

372 The incidence of COVID-19 pneumonia has reduced substantially following widespread vaccination starting in 2021 and the global dominance of Omicron SARS-CoV-2 variants 373 374 in 2022. In this context, infection with SARS-CoV-2 in hospitalised patients is often an 375 incidental finding, or is associated with non-respiratory illness, and the benefits of antiviral therapy in this setting may be limited. By contrast, RECOVERY only included patients 376 377 with pneumonia thought to be related to COVID-19. In over 80% of participants this had 378 developed despite previous COVID-19 vaccination, and in keeping with this only around 379 a quarter of participants were anti-spike antibody negative at baseline, but around three-380 guarters were anti-nucleocapsid antibody negative, indicating that this was their first 381 SARS-CoV-2 infection.

The power to perform subgroup analyses was limited even in the molnupiravir comparison, and here there was no strong signal of a differential effect of treatment in patients by antibody status, level of serum viral antigen, use of other antiviral treatments, symptom duration, or severity of illness. In patients allocated molnupiravir there was an excess of hyperglycaemia requiring insulin compared to usual care, reported in 33 vs 15 patients. An excess of hyperglycaemia was also reported in the MOVe-IN trial (9 vs 1

events), but there is no apparent mechanism to explain this, and these may represent chance findings. The increased viral clearance in day 5 nose swabs seen in those allocated molnupiravir is in keeping with its known antiviral activity, and with results from trials in early infection, although this has not previously been demonstrated in hospitalised patients.^{12,14,31,32} Nevertheless, this reduction in viral load was not shown in this trial to translate into clinical benefit.

Recruitment to the nirmatrelvir-ritonavir comparison was substantially lower than the 394 395 molnupiravir comparison, reflecting its introduction just after the initial wave of Omicron 396 in the UK in early 2022, the involvement of fewer hospital sites, and a high proportion of 397 patients for whom it was considered unsuitable. Reasons for unsuitability were not 398 systematically recorded, but this was frequently related to potential interactions between 399 ritonavir and concomitant medications. We were therefore unable to reliably assess 400 whether nirmatrelvir improves clinical outcomes, although a reduction in viral load among 401 participants allocated nirmatrelvir was observed.

402 Strengths of this trial include that it was randomised, had broad eligibility criteria, baseline 403 characterisation of markers of SARS-CoV-2 immune status and infection, and more than 404 99% of patients were followed up for the primary outcome. However, the limited sample 405 size does not allow us to exclude modest benefits of the treatments tested. Also, use of 406 other antiviral treatments was common in both comparisons, and it is possible that the 407 treatments tested may have had a greater effect in the absence of other antivirals. 408 Although this randomised trial is open label (i.e. participants and local hospital staff were 409 aware of the assigned treatment), the primary and secondary outcomes are unambiguous 410 and were ascertained without bias through linkage to routine health records in the large

411 majority of patients. However, detailed information on radiological or physiological412 outcomes was not collected

The RECOVERY trial only studied patients who had been hospitalised with COVID-19 and, therefore, is not able to provide any evidence on the safety and efficacy of these antivirals used in other patient groups. Due to the recommendation that both drugs be taken orally, and not via a gastric feeding tube, there were few patients recruited requiring invasive mechanical ventilation.

In summary, the results of this randomised trial do not support the use of molnupiravir or

419 nirmatrelvir-ritonavir as a treatment for adults hospitalised with COVID-19.

421 **Contributors**

This manuscript was initially drafted by LP, RH, PWH and MJL, further developed by the 422 Writing Committee, and approved by all members of the trial steering committee. PWH 423 and MJL vouch for the data and analyses, and for the fidelity of this report to the study 424 protocol and data analysis plan. PWH, JKB, MB, SNF, TJ, EJ, KJ, MK, WSL, AMo, AMuk, 425 426 AMum, JN, KR, GT, MM, RH, and MJL designed the trial and study protocol. MM, MC, G 427 P-A, LP, RS, DG, FH, PD, NE, JM, PH, DC, GC, SS, HE, the Data Linkage team at the RECOVERY Coordinating Centre, and the Health Records and Local Clinical Centre staff 428 429 listed in the appendix collected the data. NS did the statistical analysis. All authors 430 contributed to data interpretation and critical review and revision of the manuscript. PWH 431 and MJL had access to the study data and had final responsibility for the decision to 432 submit for publication.

434 Writing Committee (on behalf of the RECOVERY Collaborative Group):

Peter W Horby^{*}, Natalie Staplin^{*}, Leon Peto^{*}, Jonathan R Emberson, Mark Campbell, 435 436 Guilherme Pessoa-Amorim, Buddha Basnyat, Louise Thwaites, Rogier van Doorn, Raph L Hamers, Jeremy Nel, John Amuasi, Richard Stewart, Dipansu Ghosh, Fergus Hamilton, 437 Purav Desai, Nicholas Easom, Jaydip Majumdar, Paul Hine, David Chadwick, Graham 438 439 Cooke, Sara Sharp, Hanif Esmail, J Kenneth Baillie, Maya Buch, Saul N Faust, Thomas Jaki, Edmund Juszczak, Katie Jeffery, Marian Knight, Wei Shen Lim, Alan Montgomery, 440 Aparna Mukherjee, Andrew Mumford, Kathryn Rowan, Guy Thwaites, Marion Mafham[†], 441 Richard Haynes[†], Martin J Landray[†]. 442

443 *,[†] equal contribution

444 Data Monitoring Committee

- 445 Peter Sandercock, Janet Darbyshire, David DeMets, Robert Fowler, David Lalloo,
- 446 Mohammed Munavvar, Janet Wittes.

447 **Declaration of interests**

The authors have no conflict of interest or financial relationships relevant to the submitted work to disclose. No form of payment was given to anyone to produce the manuscript. All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. The Nuffield Department of Population Health at the University of Oxford has a staff policy of not accepting honoraria or consultancy fees directly or indirectly from industry (see <u>https://www.ndph.ox.ac.uk/files/about/ndph-independence-</u> <u>of-research-policy-jun-20.pdf</u>).

455 Data sharing

The protocol, consent form, statistical analysis plan, definition & derivation of clinical 456 457 characteristics & outcomes, training materials, regulatory documents, and other relevant study materials are available online at www.recoverytrial.net. As described in the protocol, 458 459 the Trial Steering Committee will facilitate the use of the study data and approval will not 460 be unreasonably withheld. Deidentified participant data will be made available to bona fide researchers registered with an appropriate institution within 3 months of publication. 461 However, the Steering Committee will need to be satisfied that any proposed publication 462 is of high quality, honours the commitments made to the study participants in the consent 463 464 documentation and ethical approvals, and is compliant with relevant legal and regulatory 465 requirements (e.g. relating to data protection and privacy). The Steering Committee will have the right to review and comment on any draft manuscripts prior to publication. Data 466 will be made available in line with the policy and procedures described at: 467 468 https://www.ndph.ox.ac.uk/data-access. Those wishing to request access should 469 complete the form at

- 470 <u>https://www.ndph.ox.ac.uk/files/about/data_access_enquiry_form_13_6_2019.docx</u>
- 471 and e-mailed to: <u>data.access@ndph.ox.ac.uk</u>
- 472

473 Acknowledgements

Above all, we would like to thank the patients who participated in this trial. We would also like to thank the many doctors, nurses, pharmacists, other allied health professionals, and research administrators at NHS hospital organisations across the whole of the UK,

supported by staff at the National Institute of Health and Care Research (NIHR) Clinical
Research Network, NHS DigiTrials, UK Health Security Agency, Department of Health &
Social Care, the Intensive Care National Audit & Research Centre, Public Health
Scotland, National Records Service of Scotland, the Secure Anonymised Information
Linkage (SAIL) at University of Swansea, and the NHS in England, Scotland, Wales and
Northern Ireland.

The RECOVERY trial was supported by grants to the University of Oxford from UK 483 484 Research and Innovation (UKRI) and NIHR (MC PC 19056), the Wellcome Trust (Grant 485 Ref: 222406/Z/20/Z) through the COVID-19 Therapeutics Accelerator, and by core 486 funding provided by the NIHR Oxford Biomedical Research Centre, the Wellcome Trust, the Bill and Melinda Gates Foundation, the Foreign, Commonwealth and 487 Development Office, Health Data Research UK, the Medical Research Council, the NIHR 488 489 Health Protection Unit in Emerging and Zoonotic Infections, and NIHR Clinical Trials Unit 490 Support Funding. TJ is supported by grants from UK Medical Research Council 491 (MC_UU_0002/14 and MC_UU_00040/03). WSL is supported by core funding provided 492 by NIHR Nottingham Biomedical Research Centre.

The views expressed in this publication are those of the authors and not necessarily thoseof the NHS, the NIHR, or the UK Department of Health and Social Care.

495 **Conflicts of interest**

496 No form of payment was given to anyone to produce the manuscript. The Nuffield 497 Department of Population Health at the University of Oxford has a staff policy of not 498 accepting honoraria or consultancy fees directly or indirectly from industry (see

- 499 https://www.ndph.ox.ac.uk/files/about/ndph-independence-of-research-policy-jun-
- 500 <u>20.pdf</u>)

501 References

5021Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a Neutralizing503Antibody Cocktail, in Outpatients with Covid-19. N Engl J Med 2021; 384: 238–51.

504 2 Gottlieb RL, Vaca CE, Paredes R, *et al.* Early Remdesivir to Prevent Progression 505 to Severe Covid-19 in Outpatients. *N Engl J Med* 2022; **386**: 305–15.

Hammond J, Leister-Tebbe H, Gardner A, *et al.* Oral Nirmatrelvir for High-Risk,
Nonhospitalized Adults with Covid-19. *N Engl J Med* 2022; published online Feb 16.
DOI:10.1056/NEJMoa2118542.

509 4 RECOVERY Collaborative Group. Casirivimab and imdevimab in patients 510 admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-511 label, platform trial. *Lancet Lond Engl* 2022; **399**: 665–76.

512 5 Bergeri I, Whelan MG, Ware H, *et al.* Global SARS-CoV-2 seroprevalence from 513 January 2020 to April 2022: A systematic review and meta-analysis of standardized 514 population-based studies. *PLoS Med* 2022; **19**: e1004107.

515 6 COVID-19 vaccine quarterly surveillance reports (September 2021 to April 2024). 516 GOV.UK. 2024; published online April 25.

517 https://www.gov.uk/government/publications/covid-19-vaccine-weekly-surveillance-

518 reports (accessed May 10, 2024).

519 7 WHO Solidarity Trial Consortium. Remdesivir and three other drugs for
 520 hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial
 521 and updated meta-analyses. *Lancet Lond Engl* 2022; **399**: 1941–53.

- Amstutz A, Speich B, Mentré F, *et al.* Effects of remdesivir in patients
 hospitalised with COVID-19: a systematic review and individual patient data metaanalysis of randomised controlled trials. *Lancet Respir Med* 2023; **11**: 453–64.
- 525 9 Yoon J-J, Toots M, Lee S, *et al.* Orally Efficacious Broad-Spectrum
 526 Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses.
 527 Antimicrob Agents Chemother 2018; **62**: e00766-18.

528 10 Sheahan TP, Sims AC, Zhou S, *et al.* An orally bioavailable broad-spectrum 529 antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple 530 coronaviruses in mice. *Sci Transl Med* 2020; **12**: eabb5883. 531 11 Strizki JM, Gaspar JM, Howe JA, *et al.* Molnupiravir maintains antiviral activity

against SARS-CoV-2 variants and exhibits a high barrier to the development of
 resistance. Antimicrob Agents Chemother 2024; 68: e0095323.

534 12 Jayk Bernal A, Gomes da Silva MM, Musungaie DB, *et al.* Molnupiravir for Oral 535 Treatment of Covid-19 in Nonhospitalized Patients. *N Engl J Med* 2022; **386**: 509–20.

Butler CC, Hobbs FDR, Gbinigie OA, *et al.* Molnupiravir plus usual care versus
usual care alone as early treatment for adults with COVID-19 at increased risk of
adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised
controlled trial. *Lancet Lond Engl* 2023; **401**: 281–93.

Arribas JR, Bhagani S, Lobo SM, *et al.* Randomized Trial of Molnupiravir or
Placebo in Patients Hospitalized with Covid-19. *NEJM Evid* 2022; 1: EVIDoa2100044.

542 15 Owen DR, Allerton CMN, Anderson AS, *et al.* An oral SARS-CoV-2 Mpro inhibitor 543 clinical candidate for the treatment of COVID-19. *Science* 2021; **374**: 1586–93.

16 Hammond J, Fountaine RJ, Yunis C, *et al.* Nirmatrelvir for Vaccinated or
545 Unvaccinated Adult Outpatients with Covid-19. *N Engl J Med* 2024; **390**: 1186–95.

Liu J, Pan X, Zhang S, *et al.* Efficacy and safety of Paxlovid in severe adult
patients with SARS-Cov-2 infection: a multicenter randomized controlled study. *Lancet Reg Health West Pac* 2023; **33**: 100694.

54918RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in550Hospitalized Patients with Covid-19. N Engl J Med 2021; **384**: 693–704.

19 RECOVERY Collaborative Group, Horby P, Mafham M, *et al.* Effect of
Hydroxychloroquine in Hospitalized Patients with Covid-19. *N Engl J Med* 2020; **383**:
2030–40.

554 20 RECOVERY Collaborative Group. Lopinavir-ritonavir in patients admitted to 555 hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform 556 trial. *Lancet Lond Engl* 2020; **396**: 1345–52.

557 21 RECOVERY Collaborative Group. Azithromycin in patients admitted to hospital
558 with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
559 Lancet Lond Engl 2021; 397: 605–12.

RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital
 with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
 Lancet Lond Engl 2021; **397**: 1637–45.

563 23 RECOVERY Collaborative Group. Convalescent plasma in patients admitted to 564 hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform 565 trial. *Lancet Lond Engl* 2021; **397**: 2049–59. RECOVERY Collaborative Group. Colchicine in patients admitted to hospital with
 COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet Respir Med* 2021; **9**: 1419–26.

569 25 RECOVERY Collaborative Group. Aspirin in patients admitted to hospital with 570 COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet* 571 *Lond Engl* 2022; **399**: 143–51.

572 26 RECOVERY Collaborative Group. Baricitinib in patients admitted to hospital with 573 COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and 574 updated meta-analysis. *Lancet Lond Engl* 2022; **400**: 359–68.

575 27 RECOVERY Collaborative Group. Empagliflozin in patients admitted to hospital
576 with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
577 Lancet Diabetes Endocrinol 2023; 11: 905–14.

578 28 RECOVERY Collaborative Group, Horby PW, Peto L, *et al.* Dimethyl fumarate in 579 patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, 580 open-label, platform trial. *Nat Commun* 2024; **15**: 924.

RECOVERY Collaborative Group. Higher dose corticosteroids in patients
 admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory
 support (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet Lond Engl* 2023; : S0140-6736(23)00510-X.

S85 30 Constantinides B, Webster H, Gentry J, *et al.* Rapid turnaround multiplex
sequencing of SARS-CoV-2: comparing tiling amplicon protocol performance. *medRxiv*2022; : 2021.12.28.21268461.

588 31 Khoo SH, FitzGerald R, Saunders G, *et al.* Molnupiravir versus placebo in
589 unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK
590 (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial. *Lancet*591 *Infect Dis* 2023; 23: 183–95.

592 32 Fischer W, Eron JJ, Holman W, *et al.* Molnupiravir, an Oral Antiviral Treatment 593 for COVID-19. 2021; : 2021.06.17.21258639.

594

Table 1: Baseline characteristics

	Molnupiravir vs usual care		Nirmatrelvir-ritonavir vs usual care		
	Molnupiravir (n=445)	Usual care (n=478)	Nirmatrelvir- ritonavir (n=68)	Usual care (n=69)	
Ane years	71 2 (14 3)	71.6 (14.0)	75.8 (13.1)	69 3 (14 1)	
<70	168 (38%)	194 (41%)	18 (26%)	30 (43%)	
>70 to < 80	140 (31%)	142 (30%)	76 (28%) 26 (38%)	22 (32%)	
>00	127 (21%)	142 (30%)	20 (3070)	17 (259/)	
≥ou Sov	137 (31%)	142 (30%)	24 (33%)	17 (25%)	
Mala	257 (59%)	200 (61%)	41 (60%)	26 (52%)	
	199 (12%)	290 (0176)	41 (00%)	30 (32 %)	
Net recorded	0 (0%)	0 (0%)	27 (40%)	0 (0%)	
Country	0 (078)	0 (078)	0 (078)	0 (0 %)	
Independent	4 (10/)	0 (20/)	0 (09/)	0 (09()	
Nepel	4 (1%) 7 (29/)	0 (2%)	0 (0%)	0 (0%)	
	7 (Z%)	11 (2%)	0 (0%)	0 (0%)	
	434 (98%)	459 (96%)	68 (100%)	69 (100%)	
		444 (070()	C4 (000()	CO (0 7 0()	
vvnite Riasia Asian and minarity athreis	395 (89%)	414 (87%)	61 (90%) 2 (40()	60 (87%)	
Black, Asian, and minority ethnic	31 (7%)	46 (10%)	3 (4%)	4 (6%)	
Unknown	19 (4%)	18 (4%)	4 (6%)	5 (7%)	
Number of days since symptom onset	5 (3-9)	5 (3-10)	4 (3-9)	5 (3-8)	
Number of days since hospitalisation	2 (1-4)	2 (1-4)	2 (1-4)	2 (1-5)	
Respiratory support received		a <i>t</i> (a a a t)		a (1 a a()	
None	66 (15%)	94 (20%)	13 (19%)	8 (12%)	
Simple oxygen	293 (66%)	309 (65%)	40 (59%)	52 (75%)	
Non-invasive ventilation	86 (19%)	73 (15%)	15 (22%)	9 (13%)	
Invasive mechanical ventilation	0 (0%)	2 (<0.5%)	0 (0%)	0 (0%)	
Biochemistry	/)	/	/	/ /	
C-reactive protein, mg/L	65 (25-135)	73 (33-137)	93 (41-148)	76 (33-167)	
Creatinine, µmol/L	81 (64-112)	79 (64-110)	76 (64-104)	72 (59-97)	
Previous diseases				/	
Diabetes	122 (27%)	126 (26%)	13 (19%)	20 (29%)	
Heart disease	146 (33%)	163 (34%)	11 (16%)	17 (25%)	
Chronic lung disease	183 (41%)	197 (41%)	22 (32%)	31 (45%)	
Tuberculosis	1 (<0.5%)	1 (<0.5%)	0 (0%)	1 (1%)	
HIV	4 (1%)	2 (<0.5%)	0 (0%)	1 (1%)	
Severe liver disease†	11 (2%)	6 (1%)	0 (0%)	0 (0%)	
Severe kidney impairment‡	33 (7%)	44 (9%)	0 (0%)	0 (0%)	
Severely immunocompromised\$	96 (22%)	87 (18%)	14 (21%)	15 (22%)	
Any of the above	335 (75%)	375 (78%)	42 (62%)	55 (80%)	
SARS-CoV-2 PCR test result					
Positive	445 (100%)	478 (100%)	68 (100%)	69 (100%)	
Negative	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
Unknown	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
Received a COVID-19 vaccine	376 (84%)	391 (82%)	57 (84%)	59 (86%)	
Use of other treatments					
Corticosteroids	389 (87%)	420 (88%)	59 (87%)	63 (91%)	
Remdesivir	178 (40%)	194 (41%)	27 (40%)	31 (45%)	
Tocilizumab	49 (11%)	56 (12%)	12 (18%)	13 (19%)	
Plan to use tocilizumab within the next 24 hours	40 (9%)	32 (7%)	2 (3%)	8 (12%)	
Randomly assigned treatments in RECOVERY					
High dose steroids	69 (16%)	87 (18%)	0 (0%)	0 (0%)	
Empagliflozin	143 (32%)	138 (29%)	19 (28%)	20 (29%)	
Sotrovimab	199 (45%)	221 (46%)	30 (44%)	35 (51%)	

	Molnupiravir	vs usual care	Nirmatrelvir-ritonavir vs usual care		
	Molnupiravir (n=445)	Usual care (n=478)	Nirmatrelvir- ritonavir (n=68)	Usual care (n=69)	
Molnupiravir	445 (100%)	0 (0%)	34 (50%)	32 (46%)	
Nirmatrelvir-ritonavir	34 (8%)	33 (7%)	68 (100%)	0 (0%)	
Viral load in baseline nose swab					
Median level (Log viral copies/ml)	6 (4-7)	6 (4-7)	6 (4-7)	6 (4-7)	
Antigen status					
Positive	212 (48%)	226 (47%)	38 (56%)	35 (51%)	
Negative	202 (45%)	212 (44%)	27 (40%)	34 (49%)	
Unknown	31 (7%)	40 (8%)	3 (4%)	0 (0%)	
Serostatus (anti N)					
Positive	114 (26%)	113 (24%)	21 (31%)	19 (28%)	
Negative	301 (68%)	325 (68%)	44 (65%)	50 (72%)	
Unknown	30 (7%)	40 (8%)	3 (4%)	0 (0%)	
Serostatus (anti S)					
Positive	334 (75%)	371 (78%)	53 (78%)	59 (86%)	
Negative	80 (18%)	67 (14%)	12 (18%)	10 (14%)	
Unknown	31 (7%)	40 (8%)	3 (4%)	0 (0%)	

Results are count (%), mean \pm standard deviation, or median (inter-quartile range). *Includes 0 pregnant women. †Defined as requiring ongoing specialist care. ‡Defined as estimated glomerular filtration rate <30 mL/min/1.73m² \$In the opinion of the managing clinician.

598 Table 2: Effect of allocation to molnupiravir and nirmatrelvir-ritonavir on key study outcomes

	Molnupiravir vs Usual care			Nirmatrelvir-ritonavir vs Usual care				
	Molnupiravir (n=445)	Usual care (n=478)	RR or mean difference (95% Cl)	p value	Nirmatrelvir- ritonavir (n=68)	Usual care (n=69)	RR or mean difference (95% Cl)	p value
Primary outcome:								
28-day mortality	74 (17%)	79 (17%)	0.93 (0.68-1.28)	0.66	13 (19%)	13 (19%)	1.02 (0.47-2.23)	0.96
Secondary outcomes:	× ,	()	, , , , , , , , , , , , , , , , , , ,			, , , , , , , , , , , , , , , , , , ,	(, , , , , , , , , , , , , , , , , , ,	
Median time to being discharged alive, days	10 (6 to >28)	9 (5 to >28)			10 (6 to >28)	8 (5 to 21)		
Discharged from hospital within 28 days	319 (72%)	354 (74%)	0.96 (0.82-1.12)	0.60	48 (71%)	54 (78%)	0.80 (0.54-1.20)	0.29
Receipt of invasive mechanical ventilation or death*	77/445 (17%)	81/476 (17%)	0.96 (0.73-1.25)	0.75	14/68 (21%)	13/69 (19%)	1.06 (0.54-2.08)	0.86
Invasive mechanical ventilation	8/445 (2%)	6/476 (1%)	1.27 (0.45-3.60)	0.65	1/68 (1%)	1/69 (1%)	-	-
Death	74/445 (17%)	78/476 (16%)	0.96 (0.73-1.26)	0.77	13/68 (19%)	13/69 (19%)	0.98 (0.49-1.94)	0.94
Subsidiary clinical outcomes								
Receipt of ventilation†	38/359 (11%)	34/403 (8%)	1.24 (0.80-1.92)	0.34	4/53 (8%)	10/60 (17%)	0.56 (0.18-1.73)	0.31
Non-invasive ventilation	35/359 (10%)	34/403 (8%)	1.14 (0.73-1.78)	0.58	4/53 (8%)	10/60 (17%)	0.56 (0.18-1.73)	0.31
Invasive mechanical ventilation	5/359 (1%)	1/403 (0%)	5.66 (0.66-48.37)	0.11	0/53 (0%)	1/60 (2%)	-	-
Successful cessation of invasive mechanical ventilation‡	0/0	0/2 (0%)	-	_	0/0	0/0	_	-
Renal replacement therapy§	5/436 (1%)	9/469 (2%)	0.62 (0.20-1.86)	0.39	0/68 (0%)	1/69 (1%)	-	-
Virological outcomes			, , , , , , , , , , , , , , , , , , ,					
Baseline-adjusted viral load (log copies/ml) on day 3	4.36 (0.09)	4.48 (0.09)	-0.13 (-0.38, 0.12)	0.32	4.04 (0.24)	4.41 (0.22)	-0.36 (-0.99, 0.26)	0.26
Baseline-adjusted viral load (log copies/ml) on day 5	3.51 (0.10)	3.99 (0.13)	-0.48 (-0.80, -0.16)	0.0037	2.90 (0.22)	3.57 (0.22)	-0.68 (-1.29, -0.07)	0.03

RR=Hazard ratio for the outcomes of 28-day mortality and hospital discharge, and risk ratio for the outcome of receipt of invasive mechanical ventilation or death (and its subcomponents). Cl=confidence interval. *Analyses exclude those on invasive mechanical ventilation at randomization. †Analyses exclude those on any form of ventilation at randomisation. ‡Analyses restricted to those on invasive mechanical ventilation at randomisation. §Analyses exclude those on haemodialysis or haemofiltration at randomisation.

599

601 Figures

602 Figure 1A: Trial profile

- 603 ITT=intention to treat. Drug unavailability and unsuitability are not mutually exclusive.
- ⁶⁰⁴ *Number recruited overall during period that adult participants could be recruited into
- 605 molnupiravir comparison.

606 Figure 1B: Trial profile

- 607 ITT=intention to treat. Drug unavailability and unsuitability are not mutually exclusive.
- ⁶⁰⁸ *Number recruited overall during period that adult participants could be recruited into
- 609 nirmatrelvir-ritonavir comparison.
- 610 Figure 2A: Effect of allocation to molnupiravir on 28-day mortality
- 611 Figure 2B: Effect of allocation to nirmatrelvir-ritonavir on 28-day mortality
- 612 Figure 3: Effect of allocation to molnupiravir on 28-day mortality by baseline
- 613 characteristics

Subgroup-specific rate ratio estimates are represented by squares (with areas of the squares proportional to the amount of statistical information) and the lines through them correspond to the 95% CIs. The ethnicity, days since onset and use of corticosteroids subgroups exclude those with missing data, but these patients are included in the overall summary diamond.

Figure 1A: Trial profile for molnupiravir comparison



ITT=intention to treat. *Number recruited overall during period that adult participants could be recruited into molnupiravir comparison.

Figure 1B: Trial profile for nirmatrelvir-ritonavir comparison



ITT=intention to treat. *Number recruited overall during period that adult participants could be recruited into nirmatrelvir-ritonavir comparison.

Figure 2: Effect of allocation to molnupiravir and nirmatrelvir–ritonavir on 28–day mortality

(A) Molnupiravir



(B) Nirmatrelvir-ritonavir



Figure 3: Effects of allocation to molnupiravir on 28–day mortality by baseline characteristics

	Molnupiravir	Usual care		Hazard ratio (95% CI)
Age, years (χ_1^2 =1.3; p=0.26)				
<70	17/168 (10.1%)	19/194 (9.8%)	← ・ +	0.87 (0.45–1.67)
≥70 <80	18/140 (12.9%)	26/142 (18.3%)	← • • • • • • • • • • • • • • • • • • •	- 0.62 (0.34–1.13)
≥80	39/137 (28.5%)	34/142 (23.9%)		1.23 (0.77–1.96)
Sex (χ ₁ ² =0.1; p=0.70)				
Men	45/257 (17.5%)	52/290 (17.9%)		0.89 (0.59–1.33)
Women	29/188 (15.4%)	27/188 (14.4%)		1.01 (0.60–1.72)
Race (χ ₁ ² =0.6; p=0.44)				
White	70/395 (17.7%)	72/414 (17.4%)		0.98 (0.71–1.37)
BAME	3/31 (9.7%)	5/46 (10.9%)	<	→ 0.55 (0.13-2.32)
Days since symptom onset (χ	² ₁ =0.3; p=0.57)			
≤7	28/150 (18.7%)	28/158 (17.7%)		1.05 (0.62–1.78)
>7	46/295 (15.6%)	51/320 (15.9%)		0.87 (0.58–1.30)
Respiratory support at rando	mization (χ_1^2 =0.3; p)=0.59) *		
None	4/66 (6.1%)	5/94 (5.3%)	←	→ 1.07 (0.29–3.99)
Simple oxygen	45/293 (15.4%)	47/309 (15.2%)		0.98 (0.65–1.48)
Non invasive ventilation	25/86 (29.1%)	26/73 (35.6%)	← ・ +	0.82 (0.47–1.42)
Invasive mechanical ventilation	0/0	1/2 (50.0%)		
Use of corticosteroids (χ_1^2 =0.2	; p=0.69)			
Yes	69/389 (17.7%)	75/420 (17.9%)	•	0.93 (0.67–1.29)
No	5/56 (8.9%)	3/56 (5.4%)	<	→ 1.25 (0.30–5.27)
Antigen status (χ_1^2 =0.4; p=0.53	3)			
Positive	40/212 (18.9%)	48/226 (21.2%)		0.89 (0.58–1.35)
Negative	30/202 (14.9%)	25/212 (11.8%)		1.10 (0.65–1.88)
Anti–N status (χ_1^2 =3.4; p=0.06))			
Positive	23/114 (20.2%)	13/113 (11.5%)	-+-	─────→ 1.69 (0.84–3.39)
Negative	47/301 (15.6%)	60/325 (18.5%)		— 0.80 (0.54–1.17)
Anti–S status (χ_1^2 =1.1; p=0.29)	1			
Positive	57/334 (17.1%)	60/371 (16.2%)		<u> </u>
Negative	13/80 (16.2%)	13/67 (19.4%)	<	0.64 (0.30–1.39)
Use of antiviral treatments (χ_1^2	=0.1; p=0.74)			
Yes	52/306 (17.0%)	55/323 (17.0%)		0.96 (0.66–1.41)
No	22/139 (15.8%)	24/155 (15.5%)	<	0.86 (0.48–1.53)
All participants	74/445 (16.6%)	79/478 (16.5%)		>> 0.93 (0.68–1.28) p=0.66
			0.5 0.75 1	1.5 2
			Molnupiravir better	Molnupiravir worse

*Trend test does not include invasive mechanical ventilation due to insufficient numbers of patients.